Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Antonio Di Stasi"'
Autor:
Katherine Parks, Kendall Diebold, Donna Salzman, Antonio Di Stasi, Zaid Al‐Kadhimi, Manuel Espinoza‐Gutarra, Ravi Bhatia, Omer Jamy
Publikováno v:
eJHaem, Vol 5, Iss 3, Pp 560-564 (2024)
Abstract Relapse remains a major cause of treatment failure following allogeneic stem cell transplantation (allo‐SCT) for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We retrospectively investigated low‐dose deci
Externí odkaz:
https://doaj.org/article/b5bc372dd90d4883a7cec32e70688817
Autor:
Corey Falcon, Lauren Smith, Mustafa Al-Obaidi, Mohammed Abu Zaanona, Katelyn Purvis, Kentaro Minagawa, Mohammad Athar, Donna Salzman, Ravi Bhatia, Frederick Goldman, Antonio Di Stasi
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Gene-modified cellular therapies carry inherent risks of severe and potentially fatal adverse events, including the expansion of alloreactive cells or malignant transformation due to insertional mutagenesis. Strategies to mitigate uncontrolled prolif
Externí odkaz:
https://doaj.org/article/e99fceecbd3b44d591957ea26258e876
Autor:
Denis F. Noubouossie, Mohammed I. A. Zaanona, Luciano J. Costa, Huy P. Pham, Marisa B. Marques, Antonio Di Stasi
Publikováno v:
Case Reports in Immunology, Vol 2022 (2022)
We present the case of a 24-year-old male, who received a minor ABO-incompatible allogeneic hematopoietic stem cell transplant (HSCT, blood group O+ ⟶ A+) from an HLA-matched unrelated female donor, as consolidation therapy for relapsed precursor-B
Externí odkaz:
https://doaj.org/article/1d12abd16c034c46bc5ea6c80fc97d2e
Autor:
Sydney Dunn-Valadez, Srilakshmi Bathini, Carly Elston, Sravanti Rangaraju, Antonio Di Stasi, Sarah Worth, Diana Morlote, Shuko Harada, Pankit Vachhani
Publikováno v:
Cancer Treatment and Research Communications, Vol 31, Iss , Pp 100560- (2022)
Ivosidenib is an oral inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1). It is approved for treatment of patients with relapsed or refractory IDH1-mutated acute myeloid leukemia (AML) and patients with newly diagnosed IDH1-mutated AML who are 75
Externí odkaz:
https://doaj.org/article/2fa1bcd8c31444e0bc126a135dcd519a
Autor:
Antonio Di Stasi
Publikováno v:
Labour & Law Issues, Vol 7, Iss 1, Pp 123-R.128 (2021)
This comment examines the corporate events of the companies belonging to the Just Eat Group. These aspects are important to try to understand if the operation is fraudulent and if the rules on the transfer of the company had to be applied.
Externí odkaz:
https://doaj.org/article/34ae6d7320624eac875d7e697277ede2
Publikováno v:
Pharmaceuticals, Vol 8, Iss 2, Pp 230-249 (2015)
T-cells genetically redirected with a chimeric antigen receptor (CAR) to recognize tumor antigens and kill tumor cells have been infused in several phase 1 clinical trials with success. Due to safety concerns related to on-target/off-tumor effects or
Externí odkaz:
https://doaj.org/article/ddaa807e992144dd863543f53709096c
Autor:
Kentaro Minagawa, Muhammad O Jamil, Mustafa Al-Obaidi, Larisa Pereboeva, Donna Salzman, Harry P Erba, Lawrence S Lamb, Ravi Bhatia, Shin Mineishi, Antonio Di Stasi
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0172640 (2017)
[This corrects the article DOI: 10.1371/journal.pone.0166891.].
Externí odkaz:
https://doaj.org/article/0c0b3c70b8574ea581f5c056b9ae8f35
Autor:
Kentaro Minagawa, Muhammad O Jamil, Mustafa Al-Obaidi, Larisa Pereboeva, Donna Salzman, Harry P Erba, Lawrence S Lamb, Ravi Bhatia, Shin Mineishi, Antonio Di Stasi
Publikováno v:
PLoS ONE, Vol 11, Iss 12, p e0166891 (2016)
Approximately fifty percent of patients with acute myeloid leukemia can be cured with current therapeutic strategies which include, standard dose chemotherapy for patients at standard risk of relapse as assessed by cytogenetic and molecular analysis,
Externí odkaz:
https://doaj.org/article/57481fa391aa4b97aff8e60674a1d1ae
Publikováno v:
Biomedicines, Vol 5, Iss 2, p 30 (2017)
Hematopoietic stem cell transplantation is a potent form of immunotherapy, potentially life-saving for many malignant hematologic diseases. However, donor lymphocytes infused with the graft while exerting a graft versus malignancy effect can also cau
Externí odkaz:
https://doaj.org/article/622dca0544c046fea807e146b1aaefc9
Autor:
Carrie L. Kitko, Mukta Arora, Zachariah DeFilipp, Mohammad Abu Zaid, Antonio Di Stasi, Vedran Radojcic, Courtney B. Betts, Lisa M. Coussens, Michael L. Meyers, Hope Qamoos, Peter Ordentlich, Vinit Kumar, Christine Quaranto, Aaron Schmitt, Yu Gu, Bruce R. Blazar, Trent P. Wang, Amandeep Salhotra, Iskra Pusic, Madan Jagasia, Stephanie J. Lee
Publikováno v:
Journal of Clinical Oncology. 41:1864-1875
PURPOSE Chronic graft-versus-host disease (cGVHD) remains the major cause of late morbidity after allogeneic hematopoietic cell transplantation. Colony-stimulating factor 1 receptor (CSF-1R)–dependent macrophages promote cGVHD fibrosis, and their e